Leadership
Artur Adib, PhD
Artur received his PhD from Brown University and was a faculty member at the National Institutes of Health, with peer-reviewed publications ranging from computer science to biophysics and quantum mechanics. He was part of the founding team at aerospace company Beta Technologies (0–$2B in under 5 years), pre-IPO engineer at Twitter, and principal engineer at Magic Leap.
Steve Wallace
Steve was a VP of Technology at Goldman-Sachs, where he joined after the successful acquisition of Dwight Asset Management ($75B+ in assets under management). Since then, he has taken on software architect roles at Green Mountain Power, iSystems, and Asure.
Jeremy Huckins, PhD
Jeremy received his PhD in Experimental and Molecular Medicine from Dartmouth College, where he also led NIH-funded research projects as a post-doc. His publications focus on the application of Machine Learning to biomedical problems, and have generated over 3,000 citations. Prior to Dartmouth, Jeremy performed research at Harvard Medical School.
Alessandra Conner, OD
Alessa has provided care in community health settings, hospital settings and private practices, and through these experiences she developed a passion for improved patient outcomes. Alessa joins with a background and interest in healthcare compliance management.
Medical advisory board
Joshua Tamayo-Sarver, MD PhD FACEP
Joshua Tamayo-Sarver is Vice President of Innovation at Vituity, one of the largest employers of doctors in the country and responsible for staffing 500 care facilities. He works clinically as a staff physician in the Emergency Department at Good Samaritan Hospital in San Jose, California, where he is the past Department Vice-Chair and Director of Quality Improvement.
Frank Peacock, MD FACEP FACC
Frank Peacock is a thought leader in biomarkers for acute care, with over 600 peer-reviewed publications. He was formerly Vice Chair of Research at Cleveland Clinic, and is presently Professor of Emergency Medicine, Associate Chair, and Research Director for the department of Emergency Medicine at the Baylor College of Medicine.
Myla Lai-Goldman, MD
Dr. Lai-Goldman spent more than 18 years at Labcorp (NYSE:LH), the last 10 years as EVP, CMO and CSO, after which she co-founded GeneCentric Therapeutics. During her tenure at LabCorp, she led all clinical, scientific and medical activities, including the introduction of more than 400 clinical assays. Dr. Lai-Goldman presently serves on the board of several public and private companies, including West Pharmaceutical (NYSE:WST) and Akoya Biosciences (NASDAQ:AKYA).
.svg)
.svg)
